查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016966

獸用治療藥物市場：2026-2032年全球市場預測（依產品類型、目標動物、給藥途徑、疾病類型、最終用戶及通路分類）

Veterinary Therapeutics Market by Product Type, Animal Type, Route Of Administration, Disease Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，獸用治療市場價值將達到 528.7 億美元，到 2026 年將成長至 553.6 億美元，到 2032 年將達到 782.9 億美元，複合年成長率為 5.76%。

主要市場統計數據
基準年 2025 528.7億美元
預計年份：2026年 553.6億美元
預測年份 2032 782.9億美元
複合年成長率 (%) 5.76%

簡要概述獸醫治療的範圍、目標和策略意義，面向臨床、商業和監管領域的相關人員。

本執行摘要首先概述了獸藥治療領域各組織面臨的策略和營運挑戰，並明確了研究範圍，涵蓋產品創新、臨床應用、監管趨勢、通路和終端用戶工作流程，從而將後續分析置於實際決策的框架內。透過界定研究範圍並清楚地識別待解決的關鍵問題，相關人員可以根據後續的證據和建議立即調整內部優先事項。

重點分析正在重塑獸醫學格局並推動整個價值鏈策略重組的變革性技術、監管和經濟變化。

在獸藥治療領域，多項融合變革正在重塑產品的研發、檢驗和動物用藥方式。生物製藥（如細胞療法、單株抗體和重組蛋白）的進步，拓展了傳統小分子藥物以外的治療選擇。同時，飼料添加劑（如酵素、益生元和益生菌）的創新，也使人們更加關注疾病預防和性能提升方面的干涉措施。此外，新一代驅蟲藥和精準疫苗正在重新定義疾病控制策略。這些產品層面的轉變正在改變研發進度、監管考量和商業化模式。

基於證據的評估，分析美國在 2025 年徵收的累積關稅將如何改變獸藥的供應鏈、成本結構和競爭格局。

美國於2025年開始實施的累積關稅造成了一系列結構性壓力，影響獸藥的籌資策略、生產經濟效益和分銷計畫。關稅導致的成本差異迫使企業重新評估其全球供應商網路，並考慮將生產外包或在地化生產，以維持獲利能力並確保供應的連續性。這種調整也影響產品生命週期管理，因為製造商必須仔細權衡集中式生產的效率和區域分散式生產能力所提供的彈性之間的利弊。

以細分市場主導的洞察，將產品、動物、給藥途徑、疾病、最終用戶和分銷細分市場轉化為可操作的洞察，用於研發、商業化和服務交付。

詳細的細分洞察揭示了不同的產品類型、動物群體、給藥途徑、疾病類型、終端用戶和分銷管道如何為整個治療領域帶來獨特的機會和挑戰。就產品而言，生物製藥（例如細胞療法、單株抗體和重組蛋白）需要專門的低溫運輸物流和監管途徑，這與專注於預防效果和農場整合的飼料添加劑（例如酵素、益生元和益生菌）截然不同。驅蟲藥分為體外寄生蟲和體內外寄生蟲，兩者的抗藥性管理需求各不相同。另一方面，藥品包括抗發炎藥物、抗生素和激素，每種藥物都有其自身的合理使用管理和處方趨勢。疫苗的差異化程度更高，每種平台（去活化疫苗、減毒疫苗和重組疫苗）都有不同的安全性特徵和給藥方案。

美洲、歐洲、中東和非洲以及亞太地區的需求推動要素、監管差異、物流限制和打入市場策略的區域概覽。

區域趨勢對法律規範、供應鏈設計和商業性實施有著深遠的影響，認知到這些差異對於制定一致的策略至關重要。在美洲，管理體制和獸醫實踐模式往往傾向於採用先進治療方法和完善的低溫運輸基礎設施，而銷售管道則由綜合批發商和專業獸醫醫院網路組成。西半球內部的跨境貿易流動也影響採購決策和物流韌性。相較之下，監管多樣性是歐洲、中東和非洲地區的顯著特徵。雖然西歐部分地區擁有嚴格的藥品安全監測系統和先進的核准流程，但該地區的其他司法管轄區則展現出不同的監管能力和市場准入複雜性，這就需要靈活的市場准入和合規策略。

對企業環境進行簡要評估，重點分析領先獸藥公司的策略定位、創新軌跡、合作模式和競爭優勢。

獸藥治療領域的商業環境呈現出多元化格局，既有成熟的製藥公司，也有專業的生物製藥研發公司、契約製造，以及專注於細分領域和平台技術的敏捷型新創公司。大型公司通常利用全球銷售網路、完善的藥物安全監測系統和整合的研發開發平臺來支援其廣泛的產品系列，而專業公司則專注於高利潤的細分治療領域，例如單株抗體、細胞療法和重組疫苗平台。契約製造組織 (CMO) 和物流專家發揮著至關重要的作用，他們能夠建立靈活的生產系統，實現規模化生產、管理低溫運輸並適應關稅變化而導致的供應鏈波動。

為行業領導者提供切實可行的策略建議，以加速永續成長和增強韌性，同時適應監管變化、關稅影響和不斷變化的臨床需求。

行業領導者應採取一系列切實可行的策略，在保持商業性成長勢頭的同時，應對監管的複雜性、關稅波動以及不斷變化的臨床需求。首先，企業必須重新設計供應鏈結構，優先考慮其韌性。這包括供應商多元化、探索關鍵零件的近岸外包，以及加強庫存管理以緩衝關稅波動的影響。其次，企業應加快對上市後監測和真實世界數據（RWE）平台的投資，以滿足日益成長的監管期望，並為疫苗、生技藥品和高觸感藥物打造差異化的價值提案。這樣做將有助於加強風險管理，並使其能夠向採購者和政策制定者提供令人信服的臨床案例。

資料來源、分析框架、細分邏輯和品管方法的透明度，以支持研究結論和相關人員的信心。

本分析的調查方法結合了定性和定量方法，以確保獲得可靠且可重複的洞見，從而為決策提供支援。主要研究包括對來自不同地區的臨床醫生、監管專家、供應鏈經理和銷售主管進行結構化訪談，以收集實用見解。次要研究整合了監管指導文件、臨床文獻和行業報告，以檢驗趨勢並為主要研究結果提供背景資訊。此外，也透過專家參與的同儕檢驗研討會進行三角驗證，以協調不同的觀點並完善策略意義。

為決策者和相關人員提供的簡明摘要，以連貫的故事形式呈現策略意義、營運重點和投資考量。

總之，獸藥產業正處於一個轉折點，其驅動力包括技術創新、不斷變化的監管環境以及商業格局的轉變。那些採用系統觀點，將產品開發、供應鏈設計、監管策略和通路執行有機結合的企業，將更有能力把科學進步轉化為永續的市場差異化優勢。先進的生技藥品、不斷發展的疫苗平台以及給藥方式偏好的改變，都使得整合證據和強力的相關人員參與變得至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 獸用治療藥物市場：依產品類型分類

  • 生技藥品
    • 細胞療法
    • 單株抗體
    • 重組蛋白
  • 飼料添加劑
    • 酵素
    • 益生元
    • 益生菌
  • 殺蟲劑
    • 體外寄生蟲控制劑
    • 體內寄生蟲控制劑
  • 製藥
    • 抗發炎藥
    • 抗生素
    • 荷爾蒙
  • 疫苗
    • 失活
    • 活病毒疫苗
    • 重組

第9章 獸用治療藥物市場：依動物類型分類

  • 水產養殖
    • 甲殼類動物
    • 淡水魚
    • 海水魚
  • 伴侶動物
    • 鳥類
    • 狗
    • 貓
    • 囓齒動物
  • 馬
    • 比賽用馬
    • 賽馬
    • 休閒馬匹
  • 家畜
    • 牛
    • 家禽
    • 綿羊/山羊
    • 豬

第10章 獸用治療藥物市場：依給藥途徑分類

  • 吸入
  • 口服
  • 腸外
    • 皮內注射
    • 肌肉內部
    • 靜脈
    • 皮下
  • 外用

第11章 獸用治療藥物市場：依疾病類型分類

  • 行為障礙
  • 感染疾病
  • 代謝性疾病
  • 肌肉骨骼疾病
  • 寄生蟲病
  • 生殖疾病

第12章 獸用治療藥物市場：依最終用戶分類

  • 門診醫療服務
  • 線上管道
  • 零售藥房
  • 動物醫院

第13章 獸用治療藥物市場：依通路分類

  • 直銷
  • 電子商務
  • 獸藥
  • 零售藥房

第14章 獸用治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 獸用治療藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 獸用治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國獸用治療藥物市場

第18章：中國獸藥市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer Aktiengesellschaft
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-034B500303A2

The Veterinary Therapeutics Market was valued at USD 52.87 billion in 2025 and is projected to grow to USD 55.36 billion in 2026, with a CAGR of 5.76%, reaching USD 78.29 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 52.87 billion
Estimated Year [2026] USD 55.36 billion
Forecast Year [2032] USD 78.29 billion
CAGR (%) 5.76%

A concise orientation that outlines the scope, objectives, and strategic relevance of veterinary therapeutics to stakeholders across clinical, commercial, and regulatory domains

This executive summary opens with a clear orientation that frames the strategic and operational imperatives facing organizations engaged in veterinary therapeutics. It establishes the scope of inquiry across product innovation, clinical application, regulatory dynamics, distribution pathways, and end-user workflows, thereby situating subsequent analysis within a pragmatic decision-making context. By defining the boundaries of the research and articulating the primary questions addressed, stakeholders can immediately align internal priorities with the evidence and recommendations that follow.

The introduction emphasizes why veterinary therapeutics warrants heightened executive attention: rising complexity in product portfolios, accelerating expectations for safety and efficacy, evolving routes of administration, and the growing importance of integrated commercial models. It also outlines the methodological approach at a high level, highlighting the synthesis of primary interviews with clinicians and industry leaders, secondary regulatory analysis, and cross-functional validation workshops. Ultimately, this opening section sets expectations for actionable insights and signals the strategic value of integrating research findings into near-term planning cycles.

A focused analysis of transformative technological, regulatory, and economic shifts reshaping veterinary therapeutics and driving strategic realignment across the value chain

The veterinary therapeutics landscape is undergoing several convergent transformations that are reconfiguring how products are developed, validated, and delivered to animal populations. Advances in biologics, including cell therapies, monoclonal antibodies, and recombinant proteins, are expanding therapeutic options beyond traditional small-molecule pharmaceuticals. Concurrently, innovation in feed additives such as enzymes, prebiotics, and probiotics is shifting attention toward preventive and performance-enhancing interventions, while next-generation parasiticides and precision vaccines are redefining disease control strategies. These product-level shifts are altering development timelines, regulatory considerations, and commercialization models.

Equally important are regulatory and commercial dynamics. Regulatory authorities are increasingly emphasizing pharmacovigilance and real-world evidence, prompting sponsors to build stronger post-market surveillance infrastructures. At the same time, digital distribution channels and e-commerce are disrupting conventional supply chains and reshaping interactions with end users. Together with greater emphasis on antimicrobial stewardship and responsible use, these trends require companies to adopt cross-functional approaches that bridge R&D, regulatory affairs, market access, and commercial operations. In short, the industry must adapt to technological progress, heightened oversight, and changing customer expectations to capture long-term value.

An evidence-based appraisal of how the cumulative United States tariffs enacted in 2025 are altering supply chains, cost structures, and competitive dynamics in veterinary therapeutics

The cumulative implementation of United States tariffs in 2025 introduced a set of structural pressures that ripple across sourcing strategies, manufacturing economics, and distribution planning for veterinary therapeutics. Tariff-induced cost differentials have compelled organizations to re-evaluate global supplier networks and to consider nearshoring or regional manufacturing to preserve margin and ensure supply continuity. This recalibration has implications for product lifecycle management, as manufacturers must weigh the trade-offs between centralized production efficiencies and the resilience offered by diversified regional capacity.

From a commercial standpoint, tariffs have elevated the importance of cost transparency and contract flexibility among distributors, hospital pharmacies, and retail partners. Companies are responding by redesigning commercial agreements, securing multi-year supplier commitments, and enhancing inventory management practices to mitigate exposure to sudden duty changes. For innovators and smaller developers, the tariff environment has increased the complexity of market entry decisions, influencing partner selection and pricing strategies. In this environment, organizations that proactively redesign their supply chains and strengthen collaborative relationships with logistics providers and distribution partners will be better positioned to maintain continuity of care for animal populations while managing margin pressure.

Segment-driven insights that translate product, animal, administration, disease, end-user, and distribution segmentations into practical implications for R&D, commercialization, and service delivery

Deep segmentation insight reveals how distinct product categories, animal populations, administration routes, disease types, end users, and distribution channels create differentiated opportunities and constraints across the therapeutic landscape. Product-wise, biologics such as cell therapies, monoclonal antibodies, and recombinant proteins demand specialized cold-chain logistics and regulatory pathways that differ markedly from feed additives like enzymes, prebiotics, and probiotics, which focus on preventive benefits and on-farm integration. Parasiticides split into ectoparasiticides and endectocides with divergent resistance management needs, while pharmaceuticals encompass anti-inflammatories, antibiotics, and hormones that each have unique stewardship and prescription dynamics. Vaccines present another axis of differentiation where inactivated, live attenuated, and recombinant platforms carry distinct safety profiles and administration protocols.

Animal-type segmentation further shapes product design and service models. Aquaculture modalities such as crustaceans, freshwater fish, and marine fish require specialized delivery systems and environmental considerations that differ from companion animals like avian, canine, feline, and rodents, which demand high-touch clinical interfaces and owner-focused communication. Equine populations-performance horses, racing horses, and recreational horses-present heterogenous therapeutic priorities tied to performance, regulatory testing, and owner investment, whereas livestock segments such as cattle, poultry, sheep and goats, and swine prioritize scalability, cost-efficiency, and herd-level interventions. Route of administration also maps to both product development and user preference: inhalation and oral options facilitate ease of use for certain species, while parenteral approaches, including intradermal, intramuscular, intravenous, and subcutaneous methods, require trained personnel and robust delivery protocols. Disease-type segmentation-behavioral disorders, infectious diseases, metabolic disorders, musculoskeletal disorders, parasitic diseases, and reproductive disorders-further informs clinical trial design and post-market support needs, shaping evidence generation strategies. End-user distinctions across ambulatory services, online channels, retail pharmacies, and veterinary hospitals influence purchasing behavior, product bundling, and educational requirements, and distribution channel choices between direct sales, e-commerce, hospital pharmacies, and retail pharmacies determine logistics, margin structures, and customer reach. By integrating these segmentation dimensions, companies can prioritize investments, tailor evidence generation, and design commercial models that align with the nuanced needs of each market niche.

A regional synthesis of demand drivers, regulatory divergence, logistical constraints, and market access strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on regulatory frameworks, supply chain design, and commercial execution, and recognizing these distinctions is essential for coherent strategy. In the Americas, regulatory regimes and veterinary practice patterns tend to favor advanced therapeutics and robust cold-chain infrastructure, while commercial channels exhibit a blend of consolidated distributors and specialized veterinary hospital networks. Cross-border trade flows within the hemisphere also shape sourcing decisions and logistics resilience. Moving across to Europe, Middle East & Africa, regulatory heterogeneity becomes a defining characteristic: while parts of Western Europe maintain stringent pharmacovigilance and progressive approval pathways, other jurisdictions within the broader region present varying levels of regulatory capacity and market access complexity, requiring adaptable market entry and compliance strategies.

The Asia-Pacific region brings its own set of dynamics, including rapid adoption of innovative platforms in certain markets, diverse animal production systems, and a strong emphasis on scalability for livestock applications. Local manufacturing capabilities, regulatory modernization in some jurisdictions, and significant e-commerce penetration are shaping new routes to market. Given these regional contrasts, companies must design differentiated approaches that account for regulatory divergence, logistics constraints, pricing sensitivity, and distribution channel maturity. Strategic regional prioritization, supported by targeted partnerships and localized clinical evidence plans, will be instrumental for organizations seeking sustainable growth across these geographies.

A concise corporate landscape assessment highlighting strategic positioning, innovation trajectories, partnership patterns, and competitive differentiators across leading veterinary therapeutics firms

The corporate landscape in veterinary therapeutics reflects a mix of established pharmaceutical firms, specialized biologics developers, contract manufacturers, and agile startups that focus on niche segments or platform technologies. Larger firms typically leverage global commercial networks, robust pharmacovigilance systems, and integrated R&D pipelines to support broad product portfolios, whereas specialized companies concentrate on high-margin therapeutic niches such as monoclonal antibodies, cell therapies, or recombinant vaccine platforms. Contract manufacturing organizations and logistics specialists play a critical role by enabling scale-up, cold-chain management, and flexible production footprints that can respond to tariff-driven supply chain shifts.

Partnerships, licensing agreements, and strategic acquisitions continue to be primary mechanisms for capability development and market entry. Collaboration between innovators and regional distributors or hospital pharmacy networks accelerates access while reducing the burden of local regulatory navigation. Moreover, companies that invest in real-world evidence generation, digital surveillance, and clinician education secure competitive advantages by strengthening trust and demonstrating long-term safety and efficacy. In this environment, differentiation derives less from basic product classes and more from how firms orchestrate integrated solutions that combine therapeutic efficacy, supply reliability, and support services for veterinarians and animal owners.

Actionable strategic recommendations that equip industry leaders to adapt to regulatory changes, tariff impacts, and evolving clinical needs while accelerating sustainable growth and resilience

Industry leaders should adopt a set of pragmatic strategies to address regulatory complexity, tariff disruption, and evolving clinical needs while preserving commercial momentum. First, organizations must redesign supply chain architectures to prioritize resilience; this includes diversifying supplier bases, evaluating nearshoring for critical components, and strengthening inventory controls to buffer against tariff volatility. Second, companies should accelerate investments in post-market surveillance and real-world evidence platforms to meet heightened regulatory expectations and to support differentiated value propositions for vaccines, biologics, and high-touch pharmaceuticals. By doing so, they will enhance risk management and provide compelling clinical narratives to purchasers and policy makers.

Third, strategic commercial realignment is necessary: firms should recalibrate channel strategies to leverage online channels and hospital pharmacy partnerships where appropriate while maintaining strong relationships with ambulatory services and retail outlets for broad access. Fourth, R&D portfolios ought to be prioritized using segmentation-informed criteria that consider route of administration, species-specific needs, and disease burden; focusing resources on platforms with clear clinical and logistical advantages will improve return on development effort. Finally, leaders must cultivate collaborative partnerships across the ecosystem, including contract manufacturers, logistics providers, and regional distributors, to accelerate market entry and manage operational risk. Implementing these recommendations in a coordinated manner will help organizations navigate near-term headwinds while positioning for long-term value creation.

Methodological transparency describing data sources, analytical frameworks, segmentation logic, and quality controls that underpin the research conclusions and stakeholder confidence

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure robust, reproducible findings and to support confident decision making. Primary research included structured interviews with clinicians, regulatory experts, supply chain managers, and commercial leaders across varied geographies to capture real-world operational insights. Secondary research integrated regulatory guidance documents, clinical literature, and industry reports to validate trends and contextualize primary findings. Triangulation occurred through cross-validation workshops with subject matter experts to reconcile divergent views and to refine implications for strategy.

Analytical frameworks employed segmentation logic across product types, animal categories, routes of administration, disease types, end users, and distribution channels to surface actionable differentiation. Quality controls included source verification, methodological audits, and scenario testing to assess sensitivity to key assumptions such as tariff shifts and regulatory policy changes. Wherever applicable, evidence hierarchies were applied to prioritize higher-quality clinical and regulatory sources. This layered methodological approach ensures that conclusions are grounded in diverse evidence streams and that recommendations are both pragmatic and defensible.

A succinct concluding synthesis that ties strategic implications, operational priorities, and investment considerations into a coherent narrative for decision makers and stakeholders

In conclusion, the veterinary therapeutics sector stands at an inflection point driven by technological innovation, regulatory evolution, and shifting commercial architectures. Organizations that adopt a systems perspective-aligning product development, supply chain design, regulatory strategy, and channel execution-will be better equipped to convert scientific advances into durable market differentiation. The combined effects of advanced biologics, evolving vaccine platforms, and changing administration preferences necessitate integrated evidence generation and robust stakeholder engagement.

Looking ahead, resilience and adaptability will define competitive advantage. Firms that proactively redesign supply networks in response to tariff and logistical pressures, invest in post-market evidence systems, and tailor offerings to the nuanced needs of species and end users will capture disproportionate value. Ultimately, success will depend on disciplined prioritization, strategic partnerships, and the ability to translate research into operational programs that improve clinical outcomes and sustain commercial performance. This synthesis should serve as a strategic compass for decision makers planning near- and medium-term actions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Therapeutics Market, by Product Type

  • 8.1. Biologics
    • 8.1.1. Cell Therapies
    • 8.1.2. Monoclonal Antibodies
    • 8.1.3. Recombinant Proteins
  • 8.2. Feed Additives
    • 8.2.1. Enzymes
    • 8.2.2. Prebiotics
    • 8.2.3. Probiotics
  • 8.3. Parasiticides
    • 8.3.1. Ectoparasiticides
    • 8.3.2. Endectocides
  • 8.4. Pharmaceuticals
    • 8.4.1. Anti-Inflammatories
    • 8.4.2. Antibiotics
    • 8.4.3. Hormones
  • 8.5. Vaccines
    • 8.5.1. Inactivated
    • 8.5.2. Live Attenuated
    • 8.5.3. Recombinant

9. Veterinary Therapeutics Market, by Animal Type

  • 9.1. Aquaculture
    • 9.1.1. Crustaceans
    • 9.1.2. Freshwater Fish
    • 9.1.3. Marine Fish
  • 9.2. Companion Animals
    • 9.2.1. Avian
    • 9.2.2. Canine
    • 9.2.3. Feline
    • 9.2.4. Rodents
  • 9.3. Equine
    • 9.3.1. Performance Horses
    • 9.3.2. Racing Horses
    • 9.3.3. Recreational Horses
  • 9.4. Livestock
    • 9.4.1. Cattle
    • 9.4.2. Poultry
    • 9.4.3. Sheep & Goats
    • 9.4.4. Swine

10. Veterinary Therapeutics Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Oral
  • 10.3. Parenteral
    • 10.3.1. Intradermal
    • 10.3.2. Intramuscular
    • 10.3.3. Intravenous
    • 10.3.4. Subcutaneous
  • 10.4. Topical

11. Veterinary Therapeutics Market, by Disease Type

  • 11.1. Behavioral Disorders
  • 11.2. Infectious Diseases
  • 11.3. Metabolic Disorders
  • 11.4. Musculoskeletal Disorders
  • 11.5. Parasitic Diseases
  • 11.6. Reproductive Disorders

12. Veterinary Therapeutics Market, by End User

  • 12.1. Ambulatory Services
  • 12.2. Online Channels
  • 12.3. Retail Pharmacies
  • 12.4. Veterinary Hospitals

13. Veterinary Therapeutics Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. E-Commerce
  • 13.3. Hospital Pharmacies
  • 13.4. Retail Pharmacies

14. Veterinary Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Veterinary Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Veterinary Therapeutics Market

18. China Veterinary Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bayer Aktiengesellschaft
  • 19.6. Boehringer Ingelheim International GmbH
  • 19.7. Ceva Sante Animale S.A.
  • 19.8. Dechra Pharmaceuticals PLC
  • 19.9. Elanco Animal Health Incorporated
  • 19.10. Merck & Co., Inc.
  • 19.11. Phibro Animal Health Corporation
  • 19.12. Vetoquinol S.A.
  • 19.13. Virbac S.A.
  • 19.14. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES VETERINARY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA VETERINARY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AMBULATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AMBULATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AMBULATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY E-COMMERCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 303. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 304. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 312. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

TABLE